PNC-27 (Peptide) – Product Details

PNC-27 is a membrane-active peptide shown in studies to selectively induce tumor necrosis and apoptosis in transformed cancer cells while sparing normal untransformed cells. Through a process that may involve pore formation in cancer cell membranes, PNC-27 has demonstrated potential anti-cancer properties against human melanoma, breast cancer, and pancreatic cancer cell lines without harming normal mammalian cells in LDH cytotoxicity assays. 

As a potential anti-cancer peptide for cancer therapeutics and treatment, in vitro, data indicates PNC-27 may promote tumor cell lysis, necrosis, and apoptosis in human cancers while allowing most normal cell growth and membrane integrity. PNC-27 may induce selective plasma membrane damage and cell death pathways only in cancer cells.

Early research shows anti-cancer and anti-tumor promise with PNC-27 across multiple human cancer cell lines, including pancreatic, melanoma, and breast cancer.

For research use and investigative purposes only. They are not approved as a drug or for therapeutic application in humans. Safety, optimal dosage, and anti-cancer efficacy have not been established. Consult your doctor before using any anti-cancer peptides.

• CAS Number: 129954-34-3
• Molar mass: 4031.7
• Chemical formula: C188H293N53O44S
• IUPAC name: Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH

What is PNC-27 Peptide?

PNC-27 is an experimental anti-cancer peptide that researchers are investigating for its potential tumor-killing effects on human subjects with cancers like melanoma, breast cancer, and pancreatic cancer. Early studies on cancer cell lines suggest PNC-27 may act as a membrane-active peptide that selectively induces tumor necrosis and apoptosis in transformed cancer cells while showing less toxicity towards normal untransformed mammalian cells. 

Through mechanisms that may involve pore formation when bound to cancer cell membranes, PNC-27 demonstrates promising anti-cancer activity against human pancreatic cancer cells, human melanoma cells, and human breast cancer cells in lab experiments. Unlike traditional cancer treatments that damage both tumor and healthy cell growth, PNC-27 appears to selectively promote cancer cell death and plasma membrane disruption in cancer cell lines while allowing normal cell survival and cell membrane integrity in untransformed cell lines. 

Ongoing research aims to explore PNC-27 as a potential anti-cancer peptide for cancer therapy and cancer treatment. Further studies are needed, but initial in vitro data and LDH cytotoxicity assays suggest the potential for PNC-27 and related membrane-residency peptides to kill cancer cells through targeted necrosis and apoptosis induction in pancreatic cancer cells, breast cancer cells, melanoma cells, and other human cancer cell lines.

By sparing normal cells while inducing tumor cell lysis and apoptosis, PNC-27 may represent an emerging class of cancer therapeutics.

Potential Applications of PNC-27 Peptide

As research on PNC-27 is in the preclinical stages, with studies limited to cell cultures and animal models thus far, comprehensive data regarding adverse effects in human subjects has not yet been established. While early experiments indicate promising anti-tumor activity against certain cancer cell lines, along with relatively selective toxicity toward malignant versus normal cells, much more testing is needed to thoroughly evaluate PNC-27’s safety across varying doses, administration routes, and treatment durations.

Therapeutic peptides may potentially treat many diseases and cancers. Compared to larger proteins or antibodies, PNC-27 peptides have benefits like:

The Anti-Cancer Peptide

Cancer is a leading cause of death worldwide. There are over 240 types of cancer tumors, each with unique mechanisms to avoid treatment. Tumors start when a cell begins replicating uncontrollably, not adhering to normal regulations. Since tumors arise from our cells, treatments need to destroy only malignant cells while keeping healthy cells intact. Most current cancer research targets all cells, but PNC-27 may target only cancer cells. [R]

The clinical study found that the HDM-2 protein is present in the outer membranes of both solid tumor cells and non-solid tumor cells like leukemia. Since leukemia cells are early-developing cancer cells, this suggests HDM-2 is expressed on the membranes of tumor cells from the start of their development. [R]

The experimental drug PNC-27 was shown to kill leukemia cells and bind to the HDM-2 proteins on their membranes at an early stage. This interaction between PNC-27 and HDM-2 is believed to poke holes in the cell membrane, resulting in the cell’s death. This was seen before in solid tumor cells. Importantly, these effects occurred in leukemia cells that lack the p53 protein. So PNC-27 may kill cancer cells through a p53-independent process. [R]

Cells in the body are constantly replicating and dying. Tumor cells form when the checkpoints that monitor cell division malfunction. The tumor becomes cancerous when the cells metastasize and spread to other body regions. Researchers are still searching for an elusive universal cure for cancer. PNC-27 shows promise as a cancer-cell-specific treatment. [R]

Until additional preclinical data helps predict reactions in human subjects more reliably, it is difficult to make definitive statements on the safety or lack of side effects of PNC-27 peptide use. As with any experimental therapeutic agent, experts would likely recommend avoiding usage outside of controlled clinical trials approved to monitor for and manage any potential adverse events.

How Does PNC-27 Peptide Work?

PNC-27 is a potential anti-cancer peptide being developed as an anti-cancer agent for cancer therapy and cancer treatment. Binding site analysis and NMR solution structure studies at SUNY Downstate Medical Center show that PNC-27 contains the same residues as naturally occurring anticancer peptides. Control experiments on normal cells and cancer cell lines, including human pancreatic cancer cells, show that PNC-27 does not kill normal cells but does kill cancer cells by causing tumor cell necrosis and tumor cell lysis. [R]

Dose-response experiments and LDH cytotoxicity assays of cancer cells treated with PNC-27 show it causes cancer cells to undergo apoptosis. Mass spectrographic analysis and x-ray crystallographic structure studies locate the binding site to the carboxyl-terminal end. Clinical trials are planned to test PNC-27 as an anti-cancer drug for cancer therapeutics and cancer treatments, including for pancreatic cancer cells. [R]

The mechanism is that PNC-27 associates with proteins like HDM-2 in the plasma membrane of the cancer cell, forming pores that break down the cell membrane, digestively lysing the cancer cell. PNC-27 occurs naturally and could be an important addition to anti-cancer agents for cancer therapy. [R]

Safety and Side Effects

As research on PNC-27 is in the preclinical stages, with studies limited to cell cultures and animal models thus far, comprehensive data regarding adverse effects in humans has not yet been established. While early experiments indicate promising anti-tumor activity against certain cancer cell lines, along with relatively selective toxicity toward malignant versus normal cells, much more testing is needed to thoroughly evaluate PNC-27’s safety across varying doses, administration routes, and treatment durations.

Until additional preclinical data helps predict reactions in human subjects more reliably, it is difficult to make definitive statements on the safety or lack of side effects of PNC-27 peptide use. As with any experimental therapeutic agent, experts would likely recommend avoiding usage outside of controlled clinical trials approved to monitor for and manage any potential adverse events. 

Some key points about potential PNC-27 side effects:

• Since it is designed to specifically target cancer cells while leaving healthy cells intact, PNC-27 may have fewer side effects than traditional chemotherapy. However, some off-target effects are still possible.
• Most reporting seems to be on its efficacy rather than safety profile. This suggests side effects have not been a major issue so far, but systematic data is lacking.
• As with any new experimental treatment, rigorous phase 1-3 clinical trials in human test subjects would be required to evaluate the short and long-term effects of PNC-27 therapy formally.
• Potential avenues for side effects could include immuno-modulation effects or unintended cell permeation effects. However, specific organ toxicities, for example, are unknown at this stage.
• Informal participants’ self-reports suggest minimal side effects compared to aggressive chemotherapy. However, controlled safety data is essential.

So in summary – PNC-27 shows promise as a potential targeted cancer therapy, but its full side effects and toxicity profile remain to be investigated in human trials. Effectiveness seems highest when peptides are combined with immune boosters, proper hydration, and reduced sugar/red meat intake.

The current lack of safety data likely reflects its early developmental status rather than known serious risks. A formal safety evaluation will clarify the side effect profile.

Frequently Asked Questions

What is PNC-27?

PNC-27,  specially designed peptides (small proteins) that may potentially destroy cancer cells while leaving healthy cells alone. 

How is it thought to work?

It may act as a “membrane-active peptide” that may disrupt cancer cell membrane integrity leading to tumor cell death.

What cancers might PNC-27 potentially treat?

So far, lab research has focused on cancers like melanoma, breast cancer, and pancreatic cancer cells.

Is PNC-27 approved for patient use yet?

No, PNC-27 remains an investigative drug in preclinical development.

Are there any known side effects?

Full safety data is not yet available, but early results suggest relative selectivity toward cancerous over normal tissue.

Why Buy PNC-27 Peptide from BehemothLabz?

BehemothLabz is the best place to purchase PNC-27 Peptide online.

We have been around since 2014, supplying the highest-quality research compounds money can buy. All of our products come with a 100% satisfaction guarantee, free and fast shipping, and a money-back guarantee on PNC-27 Peptide.

Summary

PNC-27 is a potential anti-cancer peptide developed for cancer therapy. SUNY Downstate Medical Center researchers found that PNC-27 kills human subjects’ pancreatic cancer cells, human subjects’ breast cancer cells, and other cancer cell lines while leaving normal mammalian cells and untransformed cell lines untouched in cell culture and animal studies.

Cancer cells treated with PNC-27 undergo tumor cell necrosis, tumor cell lysis, and apoptosis through a process involving PNC-27 binding to cancer cell membranes and forming pores that disrupt the membranes. Mass spectrographic analysis found that PNC-27 has amino acid residues that naturally occur in anticancer peptides and enable this cancer cell selectivity. 

LDH cytotoxicity assays, cell lysates, and transmission electron microscopy confirm that PNC-27 induces cell lysis and cell death in human participants’ cancers but untransformed and control cells are unharmed. Though some progress has been made, cancer remains hard to cure and is a leading cause of death.

Existing treatments like chemotherapy and radiation may eliminate tumors, but they also damage healthy cells. This causes difficult side effects. And cancer may still return if some cells survive treatment and spread in the body.

Many participants, unfortunately, pass away from the toxic effects of traditional treatments rather than the cancer itself. However, immunotherapy looks promising as an alternative. Instead of attacking tumors, it boosts the body’s natural defenses against cancer. This spares healthy cells. The PNC-27 peptide is an immunotherapy that may selectively target various major cancers – pancreatic, breast, skin, and leukemia. It leaves normal cells alone.

Because it is non-toxic, PNC-27 may help participants holistically defeat cancer, by supporting overall health not just killing tumors.

When given properly, PNC-27 puts cancer on the defensive. It may substantially reduce pain and extend life by unleashing the immune system against malignant cells while protecting healthy cells. More research is warranted, but PNC-27 appears one of the most effective anti-cancer approaches. Dose-response experiments demonstrate that PNC-27 may bind to cancer cell membranes and cell surfaces, forming pores that cause tumor cell necrosis, tumor cell lysis, and apoptosis in cancer cells treated with PNC-27.

LDH cytotoxicity assays confirm that PNC-27 induces cell death in pancreatic cancer cells, breast cancer cells, and other human participants’ cancers but does not kill untransformed cells.

BehemothLabz Disclaimer

Please make sure you go through the Terms and Conditions and familiarize yourself with them as it is important. Please research the scientific uses of this product before making any purchases. Make note that the packaging and labels of the product may differ from those shown on the website.

Buying the product means you agree with our Terms and Conditions. You can contact our awesome customer service team at support@behemothlabz.com if you are not fully satisfied with the product. Customer satisfaction is our number one priority!

ATTENTION: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Strength	5mg